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Abstract
Background: Plaque psoriasis is a non-contagious skin disease in which characteristic red and flaky lesions result from a
dysregulation involving both innate and adaptive immune mechanisms. Several cytokines have been implicated in these
processes and lately interleukin (IL)-36 family members have become more recognised among them. Thus far, genetic
studies have only investigated IL36RN gene of this family in relation to pustular psoriasis. Since IL36G has previously
demonstrated markedly increased levels in plaque psoriasis patients and is linked to IL-23/IL-17 axis critical in psoriasis
pathology, it was chosen to be the focus of current report.
Methods: Eleven SNPs from IL36G region were genotyped in 728 plaque psoriasis patients and 320 healthy control
individuals. Allele and haplotype frequencies between patients and controls were assessed by respective association tests.
For more specific analyses, the patients were assigned into subgroups according to sex, age of disease onset, occurrence
of psoriasis among relatives, seasonal aggravation, arthritis symptoms, body surface area (BSA) scores, and Psoriasis Area
and Severity Index (PASI) scores.
Results: The most significant results were obtained with SNPs rs28947206, rs28947207 and rs28947211 that
were associated in entire plaque psoriasis analysis (multiple testing adjusted p value (padj) = 0.0054, padj = 0.
0017 and padj = 0.0001) and also several subgroups. The first two of those SNPs were included in the same
haplotype block with rs28947205 and rs12328178, and two of the respective haplotypes, CAGC and TGTT,
provided similarly significant associations (padj = 0.0462 and padj = 0.0047).
Conclusions: The associated SNPs of this study or those in linkage disequilibrium with them could potentially
affect the functionality of IL-36γ cytokine, which in turn may impact plaque psoriasis pathology. For instance,
these variants could influence IL-36γ expression or 3D structure, thereby altering its ability to induce chemokine
production in keratinocytes and various immune cells. The precise mechanisms of these actions are currently unknown
and out of the scope of this study. To conclude, the present genetic association results confirm the proposed role of
IL-36γ in plaque psoriasis development, with corresponding causal effects to be determined in forthcoming research.
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Background
Psoriasis is a common non-infectious chronic skin disorder
that is associated with considerable physical and social bur-
den [1, 2]. Its estimated prevalence varies globally and is
highest in western countries, where it affects around 2–4%
of the population [3]. The most common form is plaque
psoriasis, accounting 90% of all cases and manifesting as
sharply demarcated erythematous plaques covered by
silvery lamellar scales. Plaques can be few or extend over
larger areas, and can also involve the entire body surface as
erythroderma in extreme cases [4]. Concurrently, it has
become evident that the effects of psoriasis are not exclu-
sively confined to the skin, a notion supported by the regu-
larly observed associations with different systemic diseases
ranging from autoimmune to cardiovascular and psychi-
atric disorders [5].
Based on the pathological mechanisms that contribute
to dermatological symptoms, psoriasis is considered an
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immune-mediated disease. The characteristic lesions de-
velop through a complex interplay between both innate
and adaptive immune system components [6]. Genetic
research has underscored the crucial role of these inter-
actions by identifying numerous susceptibility loci that
contain immune-related genes, providing valuable in-
sights into the pathogenic processes [7]. Central mecha-
nisms can be divided into 1) the cytokine-mediated
cross-talk between innate and adaptive immune systems
involving tumor necrosis factor α (TNF-α), interferon γ
(IFN-γ) and interleukin 1 (IL-1); 2) the IL-23/T helper
cell 17 (Th17) axis; and 3) the effect of immune reac-
tions on other skin cells [4].
More recently, pro-inflammatory IL-36 family cytokines
have emerged as important drivers in psoriasis pathology
[8]. All three members of the family, IL-36α, IL-36β and
IL-36γ, are overexpressed in psoriasis lesional skin [9] and
elevated IL-36α in a transgenic mouse model was shown
to induce psoriasis-like symptoms [10]. Noticeably, the
increased levels of IL-36α, IL-36β and IL-36γ in lesional
skin were in good correlation with central cytokines of
psoriasis pathology: IL-22, IL-17A, TNF-α and IFN-γ [11].
This suggests an inter-regulation that was further affirmed
by intradermal injection of IL-36α into wild-type FVB
mice, which lead to the increases of IL-36α itself, IL-17A,
IL-23, TNF-α and IFN-γ mRNA [12]. On the other hand,
injections of TNF-α, IL-17A, IL-23, IFN-γ, and IL-22 or
their combinations induced IL-36α, IL-36β and IL-36γ
[12]. All of this indicates that IL-36 cytokines synergize
with prominent IL-23/Th17 axis in producing the psoria-
sis symptoms [13]. Additionally, cathelicidin (LL37) func-
tions as an alarmin by responding to stimuli such as
infection and wounding in the skin and displays aberrant
expression in psoriasis, rosacea, and other inflammatory
skin disorders [14–16]. Considering its proposed trigger-
ing role in psoriasis [17], it is interesting to note that LL37
increases IL-36γ protein expression and release from kera-
tinocytes, that both LL37 and IL-36γ are coordinately
abundant in psoriasis epidermis and IL-36γ in turn upre-
gulates the production of chemokine (C-X-C motif) ligand
1 (CXCL1), CXCL8, CXCL10 and CCL20 in keratinocytes
[18]. Finally, from the genetics standpoint, only IL36RN
gene (encodes an antagonist IL-36Ra for common IL-36
family receptor - IL-36R) polymorphisms have been
analyzed to date, yealding associations with pustular form
of psoriasis [19–21].
In accordance with the findings described above, our
plaque psoriasis whole transcriptome analysis detected an
up-regulation of IL36A, IL36G and IL36RN gene expres-
sion in psoriasis patients [22]. This was further confirmed
in a more detailed report, wherein IL36G and IL36RN dem-
onstrated the most pronounced changes and IL-36γ was
also shown to be markedly increased on a protein level
[23]. To expand on the described observations, selected
polymorphisms of the most promising candidate, IL36G,
were genotyped in order to determine their possible associ-
ations with psoriasis susceptibility.
Methods
Study sample
The plaque psoriasis patients were recruited at the
Department of Dermatology, University of Tartu, Estonia
as described previously [24]. All were Caucasian, unrelated,
living in Estonia and had a clear clinical diagnosis of plaque
psoriasis (n = 728, age range 18–89 years). The control
group included healthy unrelated Caucasians (n = 320, age
range 18–71 years) without a personal or family history of
psoriasis. They were enrolled from medical students, health
care personnel and patients presenting at the dermato-
logical outpatient clinic with mild expression of either facial
teleangiectasis or skin tags. To conduct additional analyses,
the patients were assigned into different subgroups accord-
ing to specific subphenotypes. The early onset group con-
sisted of cases where the symptoms appeared at or before
40 years of age (n = 551) and late onset when they appeared
after 40 years of age (n = 177). Familial group included
those that had psoriasis among relatives (n = 315) and the
absence of it designated sporadic cases (n = 410). Three
groups were formed according to the body surface area
(BSA) scores: BSA ≤ 10 (n = 182), BSA 11–30 (n = 258) and
BSA ≥ 31 (n = 285). Likewise, three groups were formed
according to the Psoriasis Area Severity Index (PASI)
scores: PASI ≤10 (n = 233), PASI 11–20 (n = 225) and PASI
≥21 (n = 265). Seasonal aggravation of symptoms was used
to distinguish the spring-summer (n = 42) and fall-winter
(n = 533) groups. Patients with inflammatory arthritis
symptoms formed the PsA+ group (n = 152). Finally, male
(n = 400) and female (n = 328) patients were analysed sep-
arately against their respective controls (n = 137, n = 157).
Preparation of genomic DNA and analysis of genetic
polymorphisms
Genomic DNA was extracted from whole blood by stand-
ard high-salt extraction method and eleven single-nucleo-
tide polymorphisms (SNPs) were genotyped using the
OpenArray® Real-Time PCR Platform (Thermo Fisher Sci-
entific, Waltham, Massachusetts, USA). The selected SNPs
spanned almost the entire length of IL36G (Fig. 1).
Data analysis
The Haploview v4.2 program was used for Hardy–Wein-
berg equilibrium (HWE) calculations in control group and
subsequent allelic association and haplotype association
tests between groups of patients and controls [25]. The
Solid spine of LD algorithm (D’ > 0.8) integrated in Haplo-
view v4.2 was applied to define the haplotype blocks and
the resulting blocks were used in the haplotype association
test. Differences in allele or haplotype frequencies between
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cases and controls were assessed by chi square test. The
statistical significance threshold was set to 0.05 for all tests.
The built-in permutation module of Haploview v4.2 was
used to correct the p values for errors of multiple testing.
Ten thousand permutations were performed, resulting in
adjusted p values (padj).
Results
The genotyping procedure provided the genotypes of
eleven studied SNPs (Table 1). All were polymorphic and
met the inclusion criteria for Hardy-Weinberg equilibrium
(Hardy-Weinberg p value > 0.05).
Allelic association analysis
The strongest allelic associations were obtained with SNPs
rs28947206, rs28947207 and rs28947211 (Tables 2 and 3).
When analysing the entire psoriasis group, all three
remained significant after correcting for multiple testing
(padj = 0.0054, risk allele odds ratio (OR) 14.14, 95% confi-
dence interval (CI) 1.93–103.81; padj = 0.0017, OR 4.43, CI
1.9–10.3; padj = 0.0001, OR 4.09, CI 2.04–8.17). In addition,
rs28947206 associations withstood the correction in early
onset (padj = 0.0145, OR 12.68, CI 1.7–94.48), late onset
(padj = 0.0008, OR 18.66, CI 2.38–146.4), familial (padj =
0.003, OR 15.63, CI 2.06–118.7), sporadic (padj = 0.0122,
OR 13.08, CI 1.73–98.96), fall-winter (padj = 0.0203, OR
11.98, CI 1.6–89.71), BSA ≤ 10 (padj = 0.0207, OR 12.7 CI
1.56–103.69), BSA 11–30 (padj = 0.0015, OR 16.98, CI
2.21–130.3), BSA ≥ 31 (padj = 0.0131, OR 12.7 CI 1.63–
98.72), PASI ≤10 (padj = 0.0133, OR 12.88, CI 1.63–102.09),
and PASI ≥21 (padj = 0.0003, OR 19.01, CI 2.5–144.46)
group analyses. Rs28947207 demonstrated this in all the
same groups and also male psoriasis analysis: early onset
(padj = 0.0036, OR 4.17, CI 1.76–9.85), late onset (padj =
0.0009, OR 5.26, CI 2.05–13.47), familial (padj = 0.016, OR
3.83, CI 1.55–9.47), sporadic (padj = 0.0006, OR 4.94, CI
2.07–11.8), fall-winter (padj = 0.004, OR 4.15, CI 1.75–9.84),
BSA ≤ 10 (padj = 0.0358, OR 3.84, CI 1.45–10.21), BSA
11–30 (padj = 0.0022, OR 4.62, CI 1.86–11.49), BSA ≥ 31
(padj = 0.0015, OR 4.67 CI 1.9–11.49), PASI ≤10 (padj =
0.0351, OR 3.69, CI 1.43–9.52), PASI ≥21 (padj = 0.0001,
OR 5.97, CI 2.46–14.5), and male psoriasis (padj = 0.0191
OR 12.5, CI 1.7–91.64). Rs28947211 results remained
significant in early onset (padj = 0.0001, OR 5.08, CI 2.24–
11.48), familial (padj = 0.0019, OR 5.88 CI 2.01–17.18),
sporadic (padj = 0.0201, OR 3.26 CI 1.49–7.14), fall-winter
(padj = 0.0006, OR 4.33, CI 1.98–9.47), BSA ≤ 10 (padj =
0.0107, OR 13.21, CI 1.77–98.48), BSA ≥ 31 (padj = 0.0421,
OR 3.45, CI 1.39–8.59), PASI ≤10 (padj = 0.0119, OR 5.62,
CI 1.67–18.91), PASI 11–20 (padj = 0.0427, OR 4.18 CI
Fig. 1 IL36G gene and genotyped SNPs. The image of LD pattern was generated using the Haploview v4.2 program and black boxes indicate
haplotype blocks in entire psoriasis analysis
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1.43–12.24), and female (padj = 0.0038, OR 5.51 CI 1.92–
15.81) groups. The remaining SNPs did not produce
significant results after multiple testing correction in the
entire psoriasis group, but it did occur in certain subgroup
analyses. Namely, rs28947205 remained significant in PASI
≥21 (padj = 0.0295, OR 2.73, CI 1.36–5.48), rs12328178 in
BSA ≥ 31 (padj = 0.0483, OR 3.21, CI 1.35–7.62) and PASI
≥21 (padj = 0.0019, OR 4.25, CI 1.82–9.92), and rs34216066
(padj = 0.0031, OR 2.64, CI 1.52–4.59) in female psoriasis
analysis. Additionally, SNPs rs6707930, rs13392494 and
rs7584409 produced nominal associations in certain
subgroups, but none of these withstood the correction.
Haplotype analysis
The studied SNPs formed two haplotype blocks in the
entire psoriasis analysis (Fig. 1). The first block consisted
of rs28947205, rs12328178, rs28947206 and rs28947207
and the second block included rs6707930, rs13410389,
rs34216066, rs28947211 and rs13392494. The first block
had the same composition in all of the subgroups, whereas
the second block had the last SNP rs13392494 omitted in
early onset and BSA 11–30 analyses. In the case of famil-
ial, fall-winter, female and PASI 11–20 groups the second
block was split into two, resulting in block 2 consisting of
rs6707930 and rs13410389 and block 3 consisting of
rs34216066, rs28947211 and rs13392494.
The most significant haplotype associations involved
block 1 haplotypes CAGC and TGTT. Both of them with-
stood the correction for multiple testing in entire psoriasis
analysis (padj = 0.0462, OR 0.45, CI 0.25–0.8, and padj =
0.0047, OR 8.08, CI 2.01–32.53; Table 4). Further, TGTT
associations remained significant in early onset (padj =
0.0087, OR 7.8, CI 1.85–32.95), late onset (padj = 0.0018,
OR 10.49, CI 2.23–49.26), familial (padj = 0.0031, OR 8.7,
CI 2.07–36.49), sporadic (padj = 0.0096, OR 8.5, CI 1.84–
39.3), fall-winter (padj = 0.0112, OR 7.6, CI 1.79–32.23),
BSA 11–30 (padj = 0.0019, OR 9.54, CI 2.17–41.94), BSA ≥
31 (padj = 0.0102, OR 8.55, CI 1.8–40.58), PASI ≤10 (padj =
0.0235, OR 7.96, CI 1.62–39.02), PASI ≥21 (padj = 0.0002,
OR 11.46, CI 2.66–49.46) and male psoriasis (padj = 0.0544,
OR 15.18, CI 1.17–196.9) analyses. CAGC associations
remained significant in late onset (padj = 0.0142, OR 0.35,
CI 0.18–0.68), sporadic (padj = 0.0183, OR 0.39, CI 0.21–
0.72) and PASI ≥21 (padj = 0.0029, OR 0.34, CI 0.18–0.64)
analyses. Block 2 haplotypes did not produce as strong
associations in entire psoriasis group and the only result to
survive permutation testing involved haplotype CGCC in
early onset psoriasis (padj = 0.026, OR 0.32, CI 0.15–0.7). In
the case of block 3, haplotype CCT withstood this correc-
tion in familial (padj = 0.0057, OR 0.3, CI 0.15–0.63),
fall-winter (padj = 0.0019, OR 0.34, CI 0.19–0.62) and
female (padj = 0.0014, OR 0.24, CI 0.11–0.52) psoriasis
groups.
Discussion
Psoriasis develops in a multifactorial process influenced
by the immune system, psoriasis-associated genetic sus-
ceptibility loci, autoantigens, and various environmental
factors [26]. The possible triggers include mild trauma,
sunburn, chemical irritants, systemic drugs, occupational
risk factors impairing the skin barrier function, and HIV
infection [4]. Estimated heritability at 66–90% is among
the highest of all multifactorial genetic diseases, indicat-
ing the substantial impact of genetic susceptibility [27,
28]. The major risk loci that have been identified contain
genes related to skin barrier functions, IL-23/Th17 axis,
nuclear factor-κB and interferon signaling, and antigen
presentation, thereby uncovering pathways behind the
disease [27, 29]. Still, it is estmated that only about 25%
of psoriasis heritability has been accounted for through
all genetic discoveries published [30].
Table 1 Characteristics of studied SNPs
SNP Position pHW MAF Alleles (major/minor) Feature
rs28947205 112,978,286 1.0 0.021 C/T intron
rs12328178 112,978,391 1.0 0.013 A/G intron
rs28947206 112,978,719 1.0 0.002 G/T intron
rs28947207 112,978,748 1.0 0.011 C/T intron
rs17042686 112,979,417 0.6071 0.066 G/C intron
rs6707930 112,980,053 1.0 0.012 C/A missense (Gln34Lys)
rs13410389 112,980,446 0.7871 0.085 G/A intron
rs34216066 112,981,873 0.1303 0.095 T/C intron
rs28947211 112,981,986 1.0 0.041 T/C intron
rs13392494 112,982,098 0.175 0.464 C/T intron
rs7584409 112,985,157 0.8851 0.31 A/G 3’ UTR
pHW – Hardy-Weinberg p value
MAF – minor allele frequency among healthy controls
3’ UTR – 3′ untranslated region
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It is well established that pro-inlammatory cytokines
play a prominent role in pathways leading to psoriasis.
For instance, TNF-α released by both T cells and
antigen-presenting cells facilitates the influx of inflam-
matory cells into lesional skin through induction of
adhesion molecules, promotes the synthesis of other
pro-inflammatory mediators, and activates dermal
macrophages and dendritic cells [31]. Importantly,
TNF-α also induces the production of another pivotal
cytokine, IL-23, in myeloid dendritic cells [32]. This in
turn causes the activation of Th17 cells and the effects
of elevated IL-17, including epidermal hyperplasia, epi-
dermal cell proliferation, and leukocyte infiltration into
the skin [26]. Similarly to above cytokines, increased
expression of IL-36α, IL-36β, IL-36γ and IL-36Ra has
been detected in psoriasis patients [9, 23]. Notably, it
has been demonstrated that IL-36 can be induced in
human keratinocytes by TNF, IL-17, IL-22, and IL-36
itself; and conversely, IL-36 promotes TNF, IL-6 and
anti-microbial peptides in keratinocytes [11]. It has
been proposed, that the primary cellular effect of IL-36
cytokines in psoriasis is their impact on neutrophil in-
flammation through activation of neutrophil chemo-
kines CXCL1 and CXCL8 [33, 34]. Genetic studies have
also lend support for the relevance of IL-36 family and
have thus far focused on IL36RN. Different mutations
in this gene, that caused substantial impairments in
IL-36Ra protein, were associated with generalized pus-
tular psoriasis, a rare and severe form of the disease
[19–21]. Because our preceding findings implicated
IL-36γ as a primary suspect [22, 23], we decided to
concentrate on its gene which is located 73 kb in 5′ dir-
ection from IL36RN.
The IL36G gene is located in the chromosomal region
2q14.1 together with the rest of IL-36 subfamily genes
IL36A, IL36B and IL36RN. They all belong to the
extended IL-1 family of cytokines and the genes of its
five other members (IL1A, IL1B, IL37, IL1F10/IL38 and
IL1RN) surround the IL36 cluster. The length of IL36G
is 7653 bp, containing 5 exons. Eleven SNPs were
selected from the gene for the herein presented genetic
association analysis that provided a number of statisti-
cally significant results. The strongest among them
concerned SNPs rs28947206, rs28947207 and rs2894
7211, which were associated in entire psoriasis analysis
and also several subgroups. The first two SNPs were
included in a haplotype block and its haplotypes CAGC
and TGTT produced similarly significant associations.
From the remaining SNPs, rs28947205, rs12328178 and
rs34216066 were only associated in certain subgroup
analyses. It should be noted, that many of the accom-
panying 95% confidence intervals were large, albeit did
not cross the value of 1. This is due to the low frequen-
cies of associated alleles and haplotypes and should be
Table 3 Results of allelic association analysis
SNP Reference
allele
Control
RAF
BSA≤ 10 BSA 11–30 BSA≥ 31 PASI ≤10 PASI 11–20 PASI ≥21
RAF P value RAF P value RAF P value RAF P value RAF P value RAF P value
rs28947205 T 0.021 0.041 0.0799 0.045 0.0243 0.041 0.0504 0.036 0.1314 0.034 0.1804 0.054 0.0032
rs12328178 G 0.013 0.033 0.0344 0.033 0.0246 0.039 0.0053 0.031 0.045 0.022 0.2429 0.051 3.0E-4
rs28947206 T 0.002 0.021 0.0023 0.028 2.0E-4 0.021 0.0018 0.021 0.0018 0.017 0.0075 0.031 7.38E-5
rs28947207 T 0.011 0.039 0.0038 0.047 3.0E-4 0.048 2.0E-4 0.038 0.0039 0.036 0.0060 0.060 8.64E-6
rs17042686 C 0.066 0.098 0.0834 0.062 0.8463 0.073 0.6552 0.095 0.0982 0.071 0.7567 0.061 0.7902
rs6707930 A 0.012 0.000 0.0539 0.005 0.2288 0.008 0.5211 0.002 0.1131 0.002 0.1145 0.009 0.6308
rs13410389 A 0.085 0.056 0.1455 0.096 0.5856 0.058 0.1116 0.071 0.4649 0.083 0.9044 0.060 0.1548
rs34216066 C 0.095 0.059 0.0642 0.073 0.2135 0.059 0.0262 0.054 0.0175 0.084 0.5635 0.056 0.0193
rs28947211 C 0.041 0.003 0.0011 0.013 0.0093 0.012 0.0047 0.008 0.0017 0.010 0.0047 0.013 0.0087
rs13392494 T 0.464 0.508 0.2753 0.500 0.3266 0.534 0.0452 0.519 0.1425 0.471 0.8657 0.549 0.0159
rs7584409 G 0.310 0.308 0.9415 0.317 0.8073 0.348 0.1793 0.295 0.6002 0.303 0.8179 0.377 0.0239
RAF – reference allele frequency
P values < 0.05 after 10,000 permutations are bolded
Table 4 Results of haplotype analysis in entire psoriasis group
Haplotype Frequency Controls Patients Chi Square P value
Block 1
CAGC 0.957 0.976 0.948 7.9 0.0049
TGTT 0.020 0.004 0.028 12.198 5.0E-4
TGGT 0.016 0.018 0.016 0.076 0.7831
Block 2
CGTTC 0.493 0.509 0.486 0.88 0.3482
CGTTT 0.359 0.327 0.374 3.745 0.053
CATTT 0.080 0.083 0.078 0.109 0.7409
CGCTT 0.039 0.034 0.041 0.519 0.4714
CGCCT 0.015 0.011 0.024 4.493 0.034
P values < 0.05 after 10,000 permutations are bolded
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addressed in upcoming research by increasing the sam-
ple size.
To our knowledge, this is the first report describing
IL36G variants in relation to psoriasis or any other con-
dition. The physically closest SNP previously discussed
is rs1374284 that was associated with therapy-related
myeloid leukemia susceptibility and is located 10.3 kb
from IL36G in 3′ direction [35]. Since none of the asso-
ciated SNPs affect the peptide sequence of IL-36γ, they
may exert regulatory control over IL36G expression or
be in linkage disequilibrium with truly causal polymor-
phisms. In addition to transcription control, those causal
variants could impact the conformation of IL-36γ protein,
thereby influencing its ability to bind to IL-36R and in-
duce the downstream signals. Since proteolytic processing
of IL-36γ peptide is required to activate its proinflamma-
tory activity [36, 37], respective cleavage sites may also be
affected. However, as mentioned above, the IL36G gene
has not been thoroughly studied and possible functional
polymorphisms have not been determined. Therefore, to
confirm the significance of the genetic associations
presented here, these precise mechanisms would have to
be uncovered in future research.
Conclusions
Continuously accumulating evidence has suggested a role
for IL-36γ in psoriasis pathology and the objective of this
study was to investigate, whether the variants of its gene
could potentially be associated with the disease. For this
purpose, eleven SNPs from IL36G region were genotyped
in 728 plaque psoriasis patients and 320 healthy control
individuals. The following statistical analyses resulted in
three significantly associated SNPs and two haplotypes,
while the remaining associations were more modest. This
indicates that IL36G polymorphisms could possibly affect
IL-36γ functionality and thereby influence psoriasis suscep-
tibility. The precise mechanisms are presently unknown
and require respective experiments.
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